Ophthalmology Unit, University of Bologna and S. Orsola-Malpighi Hospital, Bologna, Italy.
Cornea. 2013 Apr;32(4):412-8. doi: 10.1097/ICO.0b013e3182580762.
We standardized quality-controlled cord blood serum (CBS)-based eye drops and evaluated the efficacy of 1-month CBS treatment in the healing of diseased corneal epithelium in severe dry eye (DE) patients.
Seventeen graft-versus-host disease (GVHD) and 13 Sjogren syndrome patients with severe persistent corneal defects were enrolled in the framework of a registered clinical trial (ClinicalTrials.gov NCT01234623). Sterile CBS eye drops were prepared to supply 0.15 ng per eye per day epithelial growth factor and administered for 1 month in a 1-day dose dispensing. The extent of epithelial defect was evaluated in square millimeters area, and subjective symptom score (Ocular Surface Disease Index score), Schirmer test I, break-up time, tear osmolarity, corneal esthesiometry (Cochet-Bonnet esthesiometer), conjunctival scraping, and imprint cytology with goblet cell count were performed at baseline (V0) and after 15 (V1) and 30 (V2, endpoint) days of treatment. Satisfaction and tolerability questionnaires were evaluated at V1 and V2.
A significant reduction was shown at the endpoint versus baseline in corneal epithelial damage (mean ± SD, 16.1 ± 13.7 vs. 40.9 ± 30 mm²/area, respectively), discomfort symptoms (Ocular Surface Disease Index score, 22.3 ± 10.3 vs. 39.3 ± 16.9), scraping cytology score (3.8 ± 1.2 vs. 6.6 ± 2.1), and tear osmolarity (312.5 ± 7 vs. 322 ± 9.1 mOsm/L), whereas a significant improvement was shown in corneal esthesiometry (48.2 ± 2.1 vs. 49.7 ± 2.1 nylon/mm/length, P < 0.05). All patients reported a high degree of satisfaction upon drop instillation.
Heterologous CBS-based eye drops represent a promising therapeutic approach in the healing of severely injured corneal epithelium and in subjective symptom relief. These drops can be obtained as readily available and quality-controlled blood derivative from cord blood banks on a routine basis.
我们对经质量控制的脐带血血清(CBS)滴眼液进行了标准化处理,并评估了 1 个月 CBS 治疗对重症干燥性眼(DED)患者病变角膜上皮愈合的疗效。
在一项已注册的临床试验(ClinicalTrials.gov NCT01234623)框架内,纳入了 17 例移植物抗宿主病(GVHD)和 13 例干燥综合征患者,他们均患有严重且持续的角膜缺损。无菌的 CBS 滴眼液被制备用于每天每只眼供应 0.15ng 上皮生长因子,并在 1 天剂量分配中使用 1 个月。通过平方毫米面积评估上皮缺损程度,同时评估主观症状评分(眼表疾病指数评分)、Schirmer 试验 I、泪膜破裂时间、泪液渗透压、角膜知觉(Cochet-Bonnet 知觉计)、结膜刮片和印迹细胞学中的杯状细胞计数。在基线(V0)和治疗后 15 天(V1)和 30 天(V2,终点)时进行评估。在 V1 和 V2 时评估满意度和耐受性问卷。
与基线相比,在终点时角膜上皮损伤(平均±标准差,16.1±13.7 与 40.9±30mm²/面积)、不适症状(眼表疾病指数评分,22.3±10.3 与 39.3±16.9)、刮片细胞学评分(3.8±1.2 与 6.6±2.1)和泪液渗透压(312.5±7 与 322±9.1mOsm/L)均显著降低,而角膜知觉(48.2±2.1 与 49.7±2.1 尼龙/mm/长度)显著改善(P<0.05)。所有患者在滴注后均报告了高度的满意度。
异体 CBS 滴眼液在严重损伤的角膜上皮愈合和主观症状缓解方面代表了一种有前途的治疗方法。这些滴眼液可以从脐带血库常规获得,并且是现成的、经过质量控制的血液衍生物。